AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%

Akili Inc

Healthcare US AKLI

NoneUSD
-(-%)

Last update at 2024-09-11T10:46:23.037816Z

Day Range

--
LowHigh

52 Week Range

0.191.67
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap32.90M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-64.18300M
  • Revenue TTM1.68M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM -0.11800M
  • Diluted EPS TTM-0.59

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -7.94500M -61.34800M -25.64500M -20.62100M
Minority interest - - - -
Net income -7.96400M -61.83000M -25.64600M -20.63400M
Selling general administrative 61.70M 42.67M 13.54M 18.88M
Selling and marketing expenses - - - -
Gross profit -0.11800M 0.18M 3.52M 18.64M
Reconciled depreciation 0.31M 0.28M 0.30M 0.25M
Ebit -90.98500M -60.71900M -25.43600M -21.49800M
Ebitda -90.67700M -60.42300M -25.01200M -20.21300M
Depreciation and amortization 0.31M 0.30M 0.42M 1.28M
Non operating income net other 84.19M - - -
Operating income -90.67700M -60.71900M -25.43600M -21.49800M
Other operating expenses 91.00M 61.26M 29.38M 41.48M
Interest expense 1.48M 0.47M 0.33M 0.16M
Tax provision 0.02M 0.00000M 0.00100M 0.01M
Interest income - - - -
Net interest income -1.48400M -0.46500M -0.33300M -0.15700M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.02M 0.48M 0.00100M 0.01M
Total revenue 0.32M 0.54M 3.94M 19.99M
Total operating expenses 90.56M 60.90M 28.96M 40.14M
Cost of revenue 0.44M 0.35M 0.42M 1.34M
Total other income expense net 82.73M -0.62900M -0.20900M 0.88M
Discontinued operations - - - -
Net income from continuing ops -7.96400M -61.34800M -25.64600M -20.63400M
Net income applicable to common shares -19.03900M -126.65700M -25.64600M -20.63400M
Preferred stock and other adjustments -7.38300M - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 80.38M 144.56M 80.94M 20.18M 43.54M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.27M 4.57M 0.97M 0.31M 0.49M
Total liab 21.85M 33.88M 15.18M 125.08M 125.79M
Total stockholder equity 58.53M 110.68M 65.76M -104.90200M -82.24800M
Deferred long term liab - - - - -
Other current liab 3.33M 5.62M 5.60M 2.57M 1.92M
Common stock 0.00800M 0.00800M 250.01M - -
Capital stock 0.00800M 0.00800M 291.88M 0.00000M 0.00000M
Retained earnings -299.78100M -240.28800M -226.11400M -114.80700M -89.16100M
Other liab - 5.51M 0.71M 1.00M 0.88M
Good will - - - - -
Other assets 0.00000M - 0.01M 0.02M 0.02M
Cash 75.45M 54.10M 76.90M 18.53M 41.20M
Cash and equivalents - - - - -
Total current liabilities 12.97M 13.60M 8.04M 3.92M 6.71M
Current deferred revenue 0.10M 0.11M 0.10M 0.37M 3.82M
Net debt -59.97000M -34.13500M -70.47700M -15.13800M -39.89200M
Short term debt 8.26M 5.20M - 0.11M -
Short long term debt 7.50M 4.38M - 0.11M -
Short long term debt total 15.48M 19.96M 6.42M 3.39M 1.30M
Other stockholder equity 358.31M 206.42M -250.00901M 9.90M 6.91M
Property plant equipment - 0.92M 1.19M 1.00M 1.26M
Total current assets 78.03M 141.04M 79.73M 19.16M 42.25M
Long term investments - - - - -
Net tangible assets - 110.68M -226.11400M -104.90200M -82.24800M
Short term investments 0.00000M 82.03M 0.00000M - -
Net receivables 0.30M 0.04M 0.03M 0.00800M 0.00000M
Long term debt 5.50M 10.44M 6.42M 3.28M 1.30M
Inventory 0.00000M 0.30M 1.83M 0.30M -
Accounts payable 1.28M 2.68M 2.35M 0.88M 0.97M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.02100M - - -
Additional paid in capital - - - - -
Common stock total equity - 0.00800M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -240.28800M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.10M 2.60M 0.01M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 2.35M 3.52M 1.20M 1.03M 1.28M
Capital lease obligations 2.49M 3.31M 0.00000M - -
Long term debt total - 10.44M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -81.17400M -0.49200M -0.11600M -0.46100M
Change to liabilities 0.09M 1.21M -3.48800M -11.52400M
Total cashflows from investing activities -81.21600M -0.49200M -0.11600M -0.46100M
Net borrowings 10.00M 3.00M 2.00M 5.00M
Total cash from financing activities 141.94M 112.84M 2.00M 4.94M
Change to operating activities -2.94500M 0.57M 1.08M -0.01200M
Net income -7.96400M -61.34800M -25.64600M -20.63400M
Change in cash -22.80200M 58.37M -22.66900M -24.90400M
Begin period cash flow 77.20M 18.83M 41.50M 66.41M
End period cash flow 54.40M 77.20M 18.83M 41.50M
Total cash from operating activities -83.52100M -53.98200M -24.55100M -29.38100M
Issuance of capital stock 0.00000M 109.68M - -
Depreciation 0.31M 0.28M 0.30M 0.25M
Other cashflows from investing activities - - - -
Dividends paid 7.38M - - -
Change to inventory - 0.86M 0.95M -
Change to account receivables -0.01200M -0.02100M -0.00800M -0.00800M
Sale purchase of stock 0.15M - - -
Other cashflows from financing activities 149.04M 114.87M 2.00M 4.94M
Change to netincome 9.82M 5.33M 3.21M 2.54M
Capital expenditures 0.04M 0.49M 0.12M 0.46M
Change receivables -0.01200M - - -
Cash flows other operating -85.76100M - - -
Exchange rate changes - - - -
Cash and cash equivalents changes -22.80200M - - -
Change in working capital -2.56000M 1.76M -2.41500M -11.53600M
Stock based compensation 9.31M 4.91M 2.90M 2.38M
Other non cash items -82.61400M 0.22M 0.31M 0.16M
Free cash flow -83.56300M -54.47400M -24.66700M -29.84200M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AKLI
Akili Inc
- -% - - - 12.31 0.35 1092.25 0.69
GEHC
GE HealthCare Technologies Inc.
0.89 1.45% 62.37 22.91 20.12 2.01 5.52 2.39 13.30
VEEV
Veeva Systems Inc Class A
-4.71 2.13% 215.95 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc
- -% 9.45 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc
0.25 4.37% 6.00 31.84 26.25 0.05 4.60 0.04 0.12

Reports Covered

Stock Research & News

Profile

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Akili Inc

No. 312, 71 Commercial Street, Boston, MA, United States, 02109

Key Executives

Name Title Year Born
Dr. Walter Edward Martucci Ph.D. Co-Founder, CEO & Director 1982
Dr. Adam Gazzaley M.D., Ph.D. Co-founder, Chief Science Advisor & Director 1969
Mr. Santosh Shanbhag CFO & Treasurer 1977
Ms. Jacqueline L. Studer J.D. Chief Legal Officer, Gen. Counsel & Sec. 1959
Mr. Matthew Franklin M.B.A. Pres & COO 1973
Mr. Matthew Omernick Co-Founder & Chief Creative Officer NA
Mr. Carl Gottlieb Chief Technology Officer NA
Ms. Julie DiCarlo Sr. VP of Communications NA
Ms. Barrie Brian Sr. VP of People NA
Dr. Scott H. Kollins Ph.D. Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.